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which directly and indirectly affect the 
occurrence and distribution of malaria 
(10). Whether malaria will return as a 
major health threat likely depends on 
the size and fragmentation of the in-
dividual plantation areas. The required 
size of a plantation for the survival of 
the vector population is unclear, but 
large areas of plantation tend to offer 
dense vegetation and, therefore, high 
humidity  and  shade,  which  provide 
suitable environmental conditions for 
larval  habitats,  even  during  the  dry 
season  (8).  Conversely,  during  the 
rainy season, conditions at the edges 
of  fragmented  forests,  where  human 
settlements are often located, become 
favorable  for  larval  habitats,  render-
ing villagers susceptible to the disease 
(6). In addition to changes in habitat 
and  microclimate,  social  or  political 
changes in the region may affect the 
transborder movement of malaria into 
Thailand  with  consequences  for  po-
tential reemergence (7). 
Although the association between 
rubber plantations and malaria is well 
known in Southeast Asia, the poten-
tial  for  reemergence  should  receive 
substantially more attention from eco-
nomic, agricultural, and environmen-
tal planning bodies. Changes in land 
use and land cover have the potential 
to facilitate the transmission of disease 
to  humans.  Understanding  the  influ-
ence of land use change on malaria oc-
currence is critical for shaping future 
surveillance and control strategies.
Acknowledgments
Horst Taraschewski kindly read and 
commented  on  the  manuscript,  and  an 
anonymous reviewer provided useful in-
formation.
The National University of Singapore 
provided support through Young Investiga-
tor Award funding (R-109-000-070-123). 
T.P.’s travel was funded by the Deutsche 
Forschungsgemeinschaft (PE 11/1-1).
Trevor Petney,  
Paiboon Sithithaworn,  
Rojchai Satrawaha,  
Carl Grundy-Warr,  
Ross Andrews, Yi-Chen Wang, 
and Chen-Chieh Feng
Author	affiliations:	University	of	Karlsruhe,	
Karlsruhe,	 Germany	 (T.	 Petney);	 Khon	
Kaen	University,	Khon	Kaen,	Thailand	(P.	
Sithithaworn);	 Mahasarakham	 University,	
Mahasarakham,	Thailand	(R.	Satrawaha);	
National	University	of	Singapore,	Singapore	
(C.	Grundy-Warr,	Y.-C.	Wang,	C.-C.	Feng);	
and	University	of	South	Australia,	Adelaide,	
South	Australia,	Australia	(R.	Andrews)
DOI:	10.3201/eid1508.090240
References
  1.   van Beilen JB, Poirier Y. Establishment of 
new crops for the production of natural rub-
ber. Trends Biotechnol. 2007;25:522–9.
  2.   Food  and Agriculture  Organization.  Se-
lected indicators of food and agriculture 
development in Asia Pacific Region 1992–
2002. Bangkok: The Organization; 2003.
  3.   Rubber Research Institute of Thailand [in 
Thai] [cited 2009 Jun 24]. Available from 
http://www.rubberthai.com
  4.   Wright H. Hevea brasiliensis, or para rub-
ber, its botany, cultivation, chemistry and 
diseases,  2nd  ed.  Colombo  (Sri  Lanka): 
A.M. & J. Ferguson; 1906.
  5.   Chareonviriyaphap  T,  Bangs  MJ,  Ra-
tanatham  S.  Status  of  malaria  in  Thai-
land. Southeast Asian J Trop Med Public 
Health. 2000;31:225–37.
  6.   Obsomer V, Defourny P, Coosemans M. 
The  Anopheles  dirus  complex:  spatial 
distribution  and  environmental  drivers. 
Malar J. 2007;6:26. DOI: 10.1186/1475-
2875-6-26
  7.   Thimasarn K, Jatapadma S, Vijaykadga S, 
Sirichaisinthop J, Wongsrichanalai C. Epi-
demiology of malaria in Thailand. J Travel 
Med. 1995;2:59–65. DOI: 10.1111/j.1708-
8305.1995.tb00627.x
  8.   Yasuoka J, Levins R. Impact of defores-
tation  and  agricultural  development  on 
anopheline ecology and malaria epidemi-
ology. Am J Trop Med Hyg. 2007;76:450–
60.
  9.   Lindblade  KA,  Walker  ED,  Onapa AW, 
Katungu J, Wilson ML. Land use change 
alters  malaria  transmission  parameters 
by modifying temperature in a highland 
area  of  Uganda.  Trop  Med  Int  Health. 
2000;5:263–74.  DOI:  10.1046/j.1365-
3156.2000.00551.x
10.   Fantini  B. Anophelism  without  malaria: 
an ecological and epidemiological puzzle. 
Parassitologia. 1994;36:83–106.
Address  for  correspondence:  Trevor  Petney, 
Institute of Zoology 1: Ecology and Parasitology, 
University  of  Karlsruhe,  Kornblumen  Strasse 
13, Karlsruhe, Germany; email: trevor.petney@
bio.uka.de
Fatal Borreliosis  
in Bat Caused by 
Relapsing Fever 
Spirochete, United 
Kingdom
To the Editor: Tick-borne relaps-
ing fevers caused by members of the 
genus Borrelia have been encountered 
throughout Africa, Asia, the Americas 
and,  rarely,  in  southern  Europe  (1). 
The Borrelia species associated with 
relapsing fevers form a monophyletic 
group within the genus, although not 
all  members  of  this  group  have  yet 
been implicated as agents of human 
disease. For example, a novel spiro-
chete that is closely related to the re-
lapsing fever agent Borrelia turicatae 
has recently been detected in Carios 
kelleyi, an argasid bat tick (2,3). We 
report  the  discovery  of  a  spirochete 
causing fatal borreliosis in a bat in the 
United Kingdom.
The  infected  bat  was  a  juvenile 
female  Pipistrellus  species  that  was 
found alive but on the ground near the 
town  of  Mevagissy  in  southwestern 
England in August 2008; despite reha-
bilitation efforts, it died a few days lat-
er. A postmortem examination showed 
pale skeletal muscles, anemia, excess 
blood-tinged  pleural  fluid,  a  healthy 
thymus, but enlarged cranial thoracic 
lymph  nodes.  The  liver  was  greatly 
enlarged and mottled, the spleen was 
also large and unusually dark, and the 
adrenal glands were enlarged and pale 
with  areas  of  hemorrhage.  The  kid-
neys were pale with a fine speckling LETTERS
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pattern  over  the  cortex.  Histopatho-
logic examination of the liver showed 
multifocal necrosis and vacuolation of 
hepatocytes  and  infiltration  by  mac-
rophages. The lungs were congested 
and infiltrated by inflammatory cells, 
and  large  numbers  of  granulocytes 
were found in the blood vessels. The 
spleen showed marked extramedullary 
hemopoiesis.  Tissue  sections  stained 
by  the  Warthin-Starry  technique  ex-
hibited numerous long, undulating, ar-
gophilic bacilli. These organisms were 
present in large numbers in the liver 
lesions (Figure), but were also found 
in the parenchyma of lung and spleen 
and in blood vessels.
On  the  basis  of  these  observa-
tions,  a  diagnosis  of  fatal  hepatitis 
and septicemia caused by a spirochete 
was made. DNA from the bat’s liver 
was extracted and analyzed by using 
a PCR specific for an almost complete 
fragment of the 16S rRNA-encoding 
gene,  as  previously  described  (4), 
but with an annealing temperature of 
45°C. This DNA extract was also in-
corporated into PCR assays targeting 
glpQ and flaB gene fragments (5). The 
products of these reactions were se-
quenced, and sequence data were as-
sembled and analyzed by using Staden 
(6) and MEGA (7).
We  obtained  unambiguous  se-
quence  data  for  all  3  loci,  compris-
ing of 1,364 bp of the 16S rRNA-en-
coding gene (GenBank accession no. 
FJ868583), 1,239 bp of flaB and flank-
ing  regions  (GenBank  accession  no. 
FJ868584), and 480 bp of glpQ (Gen-
Bank accession no. FJ868585). Each 
of these was aligned with homologous 
sequences available for other Borre-
lia species and used for phylogenetic 
analyses. Inferences made by using all 
loci were congruent, with the UK bat–
associated  spirochete  lying  close  to, 
but distinct from, a cluster containing 
B. recurrentis, B. duttonii, and B. cro-
cidurae (Figure; data not shown).
These  3  species  are  associated 
with  relapsing  fevers  in  Africa  and 
Asia.  The  UK  bat–associated  spiro-
chete  bore  no  specific  evolutionary 
relatedness to B. johnsonii, the newly 
characterized  member  of  the  relaps-
ing  fever  group  of  Borrelia  species 
associated with C. kellyi in the United 
States (Figure) (3). An Argas vesper-
tilionis larval tick was found attached 
to the infected bat and may have been 
the source of its infection. PCR was 
not performed on the tick because it 
was near-replete with blood that was 
intensely  infected  with  spirochetes. 
A.  vespertilionis,  commonly  known 
as the short-legged bat tick, is widely 
distributed, parasitizing numerous bat 
species across Europe, southern Asia, 
and North Africa (8).
Given the close relationship be-
tween the novel spirochete we encoun-
tered  and  known  pathogens,  the  re-
ported propensity of A. vespertilionis 
to bite humans (9), and the wide geo-
graphic range of this tick, our findings 
have  repercussions  for  public  health 
in many parts of the Old World. Fur-
thermore, although bats are likely the 
reservoir host for this organism, our 
study also identifies it as a pathogen, 
and as such its discovery has implica-
tions for the conservation of numerous 
threatened bat species across Europe 
and throughout the world.
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Past, Present, and 
Future of Japanese 
Encephalitis
To the Editor: We are writing in 
response to the perspective on Japanese 
encephalitis (JE) by Erlanger et al. (1). 
Growing  awareness  is  encouraging, 
yet because JE is a largely neglected 
disease,  information  is  often  contra-
dictory  or  not  readily  available.  We 
would like to supplement the authors’ 
review with clarification on available 
vaccines and actions countries are tak-
ing to evaluate and control JE.
There  is  room  for  improvement 
or expansion on collecting and report-
ing JE surveillance data. However, as 
vaccine  availability  increases,  many 
countries are eager to determine the 
impact of JE and to make informed 
decisions on immunization programs. 
For  example,  surveillance  in  Indo-
nesia  from  2005  through  2006  con-
firmed  human  cases  throughout  the 
country (2). In Cambodia, JE surveil-
lance commenced in 2006, and an im-
munization program is being planned 
(2). Regional JE laboratory networks 
established by the World Health Or-
ganization are also helping countries 
gather this information by strengthen-
ing diagnostic capacity.
Cambodia plans to introduce the 
live,  attenuated  SA  14-14-2  vaccine 
from  China’s  Chengdu  Institute  of 
Biological Products. This vaccine has 
recently become internationally avail-
able and is increasingly replacing the 
inactivated, mouse brain–derived vac-
cine in Asia. A single dose of the SA 
14-14-2  vaccine  demonstrated  96% 
efficacy after 5 years (3), and the In-
stitute’s commitment to an affordable 
price  for  developing  countries  has 
broadened accessibility (4). The gov-
ernment  of  India  introduced  the  SA 
14-14-2 vaccine in 2006, and nearly 
50 million children 1–15 years of age 
have been reached through vaccination 
campaigns and routine immunization. 
The vaccine also is available through 
public programs or private markets in 
China, Nepal, South Korea, Sri Lanka, 
and Thailand.
JE  vaccine  candidates  in  late-
stage  development  for  children  in-
clude a live, attenuated chimeric virus 
vaccine and an inactivated, Vero cell–
derived vaccine, each based on the SA 
14-14-2  virus  strain. Additionally,  2 
inactivated,  Vero–cell  derived  vac-
cines based on the Beijing-1 strain are 
being developed in Japan (5).
New vaccine development, along 
with progress in surveillance and im-
munization, offers promise for sustain-
able control of clinical JE. To achieve 
this, global partners are working to-
gether to develop a strategic plan for 
JE control by 2015 (6).
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